ArQule Inc. (ARQL)

[gfp927z]

SGXP has a highly selective MET compound in late preclinical stage, still unpartnered -

>>> MET Kinase Inhibitor for Solid Tumors
We have selected SGX523 as a development candidate with a target of filing an INDin the first quarter of 2008. MET inhibitor compounds currently in clinical development have shown promising indications of patient benefit in several solid tumor indications, including lung, colon, prostate and renal cancer. SGX523 has a number of attractive properties, including low molecular weight, exquisite selectivity (1000-fold more selective for MET over more than 200 human kinases), good cell-based potency, good oral bioavailability, and excellent drug-like properties. The Company’s FAST drug discovery platform, leveraging structure-based design, proved highly advantageous for discovering selective MET inhibitors. SGX 523 is well tolerated in rodents, has demonstrated in vivo efficacy in mice, and has good safety pharmacology and ADME properties. <<<